NSAID Request in a Patient With Heart Failure and CKD
Mrs. L is a 74-year-old woman with heart failure with reduced ejection fraction (EF 32%), stage 3b chronic kidney disease (eGFR 38 mL/min/1.73 m²), and type 2 diabetes. Her medications are furosemide 40 mg BID, sacubitril/valsartan 97/103 mg BID, spironolactone 12.5 mg daily, metformin 500 mg BID, and empagliflozin 10 mg daily. She visits the community pharmacy with a new prescription for naproxen 500 mg BID for knee osteoarthritis from a walk-in clinic. She reports three days of worsening knee pain, no swelling, no fever. Blood pressure is 128/76 mmHg, heart rate 72, weight stable, no dyspnea. Her last potassium was 4.9 mmol/L and creatinine 132 µmol/L. She says she took naproxen years ago without problems and wants quick relief before a family event this weekend. She asks whether the naproxen is okay.
1. Identify the main safety concerns with naproxen in this patient and explain the mechanism for each.
Read the worked answer
Heart failure decompensation: NSAIDs inhibit COX-1 and COX-2, reducing renal prostaglandin synthesis. This causes sodium and water retention, increased preload, and peripheral vasoconstriction, which can precipitate edema and HF exacerbation.
Acute kidney injury: Prostaglandins maintain afferent arteriolar dilation when renal perfusion is reduced. Blocking them, especially with concurrent sacubitril/valsartan (neprilysin/ARB), furosemide, and empagliflozin, increases AKI risk (the 'triple whammy' concept).
Hyperkalemia: NSAID-induced hyporeninemic hypoaldosteronism plus spironolactone and sacubitril/valsartan can raise potassium; her K is already 4.9 mmol/L.
GI bleeding: COX-1 inhibition reduces gastric mucosal protection.
Blood pressure elevation: Sodium retention and vasoconstriction may worsen BP control. Age and CKD amplify all these risks.
2. Recommend an alternative analgesic plan, including nonpharmacologic and pharmacologic options, with monitoring.
Read the worked answer
- First-line: acetaminophen 500–1000 mg PO every 6 hours as needed, maximum 3 g/day (lower if frailty or hepatic risk). Counsel about hidden acetaminophen in combination products.
- Topical NSAID: diclofenac 1% gel 2–4 g to the knee four times daily. Systemic exposure is lower than oral NSAIDs, but it is not zero; monitor for edema and renal effects.
- Nonpharmacologic: ice, activity modification, physiotherapy, weight management, and a cane if needed.
- If inadequate: refer to the prescriber for intra-articular corticosteroid or specialist assessment.
- Monitoring: pain and function; daily weight; BP; edema or dyspnea. If any systemic NSAID is used, check creatinine and potassium at baseline and within 1 week.
- Avoid: oral naproxen, other oral NSAIDs, and aspirin for analgesia.
3. The walk-in clinic prescriber insists on naproxen. What is your response?
Read the worked answer
- State clearly that naproxen is not appropriate given HFrEF, CKD stage 3b, and the interacting regimen. The risk of AKI, HF decompensation, hyperkalemia, and GI bleed outweighs the benefit.
- Contact the prescriber, explain the specific concerns, and recommend acetaminophen plus topical diclofenac and nonpharmacologic measures.
- If the prescriber still insists, document the discussion and recommend the lowest effective dose for the shortest duration (for example, naproxen 250 mg BID for no more than 3–5 days), with a PPI if GI risk is present, and close monitoring of weight, BP, creatinine, and potassium.
- Educate the patient on warning signs: weight gain, swelling, shortness of breath, decreased urine output, black stools, or unusual bruising.